Literature DB >> 19578242

Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006.

Bakhao Ndiaye1, Karim Ould-Kaci, Julia Salleron, Pierre Bataille, Frederique Bonnevie, Philippe Choisy, Karine Cochonat, Clotilde Fontier, Habib Guerroumi, Faiza Ajana, Pascal Chaud, Yazdan Yazdanpanah.   

Abstract

BACKGROUND: Our goal was to determine the incidence rate and risk factors for loss to follow-up (LTFU) of HIV-infected patients in Northern France.
METHODS: We estimated the incidence rate of LTFU in 1,007 HIV-infected patients under care from January 1997 to December 2006. We then investigated potential risk factors for LTFU at inclusion and during follow-up.
RESULTS: The incidence of LTFU was estimated to be 3.5 per 100 person-years. Risk factors for LTFU at enrolment in a multivariate Cox model were age <30 years (hazard ratio [HR] 1.66 versus >40 years, 95% confidence interval [CI] 1.04-2.64), transmission by injection drug use (HR 5.26 versus men who have sex with men, 95% CI 2.90-9.52), no phone number provided (HR 5.4, 95% CI 3.6-8.2), no primary care physician (HR 2.10, 95% CI 1.25-3.52) and sub-Saharan African origin (HR 2.09, 95% CI 1.36-3.22). Patients with CD4(+) T-cell counts <200 cells/mm(3) (HR 0.49 versus >/=350 cells/mm(3), 95% CI 0.32-0.76) and 200-349 cells/mm(3) at baseline (HR 0.63 versus >/=350 cells/mm(3), 95% CI 0.41-0.98) had a decreased risk of LTFU. During follow-up, the risk of LTFU increased when the most recent CD4(+) T-cell count was <200 cells/mm(3) (HR 2.06, 95% CI 1.16-3.66), the patient was not on highly active antiretroviral therapy (HAART; HR 4.20, 95% CI 2.66-6.61) and the patient was on HAART but had a detectable viral load (HR 1.92, 95% CI 1.19-3.01).
CONCLUSIONS: Our findings will help clinicians recognize patients who require additional support for retention in care, including younger patients, injection drug users, people of sub-Saharan African origin, patients who are healthier at enrolment and patients who do not adhere to HAART during follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19578242

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  18 in total

1.  Effect of Health Literacy on Research Follow-Up.

Authors:  Cardella Leak; Kathryn Goggins; Jonathan S Schildcrout; Cecelia Theobald; Katharine M Donato; Susan P Bell; John Schnelle; Sunil Kripalani
Journal:  J Health Commun       Date:  2015

2.  Co-morbid Non-communicable Diseases and Associated Health Service Use in African and Caribbean Immigrants with HIV.

Authors:  Khatundi-Irene Masindi; Nathaniel Jembere; Claire E Kendall; Ann N Burchell; Ahmed M Bayoumi; Mona Loutfy; Janet Raboud; Sean B Rourke; Henry Luyombya; Tony Antoniou
Journal:  J Immigr Minor Health       Date:  2018-06

Review 3.  The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.

Authors:  Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

4.  Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis.

Authors:  S Krishnan; K Wu; M Smurzynski; R J Bosch; C A Benson; A C Collier; M K Klebert; J Feinberg; S L Koletar
Journal:  HIV Clin Trials       Date:  2011 Jul-Aug

5.  Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa.

Authors:  Martin W G Brinkhof; Ben D Spycher; Constantin Yiannoutsos; Ralf Weigel; Robin Wood; Eugène Messou; Andrew Boulle; Matthias Egger; Jonathan A C Sterne
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

6.  The Effect of Timing of Initiation of Antiretroviral Therapy on Loss to Follow-up in HIV-Tuberculosis Coinfected Patients in South Africa: An Open-Label, Randomized, Controlled Trial.

Authors:  Nonhlanhla Yende-Zuma; Kogieleum Naidoo
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

7.  Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007.

Authors:  Bakhao Ndiaye; Julia Salleron; Anne Vincent; Pierre Bataille; Frédérique Bonnevie; Philippe Choisy; Karine Cochonat; Clotilde Fontier; Habib Guerroumi; Bernard Vandercam; Hugues Melliez; Yazdan Yazdanpanah
Journal:  BMC Infect Dis       Date:  2011-01-12       Impact factor: 3.090

Review 8.  HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes.

Authors:  Wim Delva; Jeffrey W Eaton; Fei Meng; Christophe Fraser; Richard G White; Peter Vickerman; Marie-Claude Boily; Timothy B Hallett
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

9.  Characteristics and consequences of medical care interruptions in HIV-infected patients in France.

Authors:  L Cuzin; P Dellamonica; Y Yazdanpanah; S Bouchez; D Rey; B Hoen; A Cabié
Journal:  Epidemiol Infect       Date:  2016-04-01       Impact factor: 4.434

10.  Implementation of mental health service has an impact on retention in HIV care: a nested case-control study in a japanese HIV care facility.

Authors:  Shinjiro Tominari; Takahiro Nakakura; Toshihiko Yasuo; Kyoko Yamanaka; Yoshimitsu Takahashi; Takuma Shirasaka; Takeo Nakayama
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.